Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity
Open Access
- 30 December 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (3) , 449-457
Abstract
Patients with autoimmune rheumatic diseases with a previous infection by the SARS-CoV-2 virus have exaggerated responses to a single dose of COVID-19 vaccination as compared to fully vaccinated infection naive patients. The second dose is currently recommended at an extended gap after the infection, but the information available regarding response to the second dose in this subgroup is limited. Patients with AIRDs previously infected with COVID-19, who have received at least one dose of AZD1222/ChAdOx1 (n = 200) were included and stratified based on vaccine doses (V), and infection (I) into I + V, I + V + V, V + I, V + V + I. Anti-RBD (receptor binding domain) antibodies were compared across the four groups. In 49 patients of the I + V + V group (AZD12222), paired sera were compared for antibody levels and neutralization after each vaccine dose. Thirty patients with hybrid immunity after BBV152 and 25 with complete vaccination without infection were included as controls. The highest anti-RBD antibody levels were observed in the V + V + I group (18,219 ± 7702 IU/ml) with statistically similar titers in the I + V + V (10,392 ± 8514 IU/ml) and the I + V (8801 ± 8122 IU/ml). This was confirmed in the 49 paired samples that paradoxically showed a lowering of antibody titers after the second dose [9626 (IQR: 4575–18,785)–5781 (2484–11,906); p < 0.001]. Neutralization of the Delta variant was unaffected but Omicron neutralization was significantly reduced after the second dose [45.7 (5.3–86.53)–35% (7.3–70.9); p = 0.028]. Ancillary analyses showed that only the hybrid immune sera could neutralize the Omicron variant and AZD1222 hybrids performed better than BBV152 hybrids. The second dose of AZD1222 did not boost antibody titers in patients with RD who had COVID-19 previously. In the analysis of paired sera, the second dose led to a statistically significant reduction in antibody titers and also reduced neutralization of the Omicron variant.Keywords
This publication has 30 references indexed in Scilit:
- Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional studyRheumatology International, 2021
- SARS-CoV-2 Antibody Response in Persons with Past Natural InfectionNew England Journal of Medicine, 2021
- Hybrid immunityScience, 2021
- Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional surveyRheumatology International, 2021
- First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19Journal of Clinical Investigation, 2021
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2JAMA, 2021
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA VaccineNew England Journal of Medicine, 2021
- Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individualsThe Lancet, 2021
- SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisisRheumatology International, 2021
- A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admissionIntensive Care Medicine, 1996